Idexx Laboratories (IDXX)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$535.38+1.15%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · IDXX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks IDXX against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Management has consistently raised and narrowed 2026 revenue guidance, emphasizing growth driven by Companion Animal Group Diagnostics recurring revenue and organic growth.
Stated as a priority in 4 of last 4 quarters. Revenue grew from initial 2026 guidance range of $4,632M-$4,720M at 2025-Q4 to $4,700M-$4,745M at 2026-Q2, reflecting reported growth guidance increase from 8.6%-10.6% to 9.1%-10.3%. Management has consistently raised and narrowed revenue guidance, delivering on growth expectations.
“Narrowed 2026 revenue guidance to $4,700 million - $4,745 million, up $5 million at midpoint, reflecting benefit of CAG Diagnostics recurring revenue performance.”
“Increases 2026 revenue guidance to $4,675 million - $4,760 million, up $42 million or ~1% at midpoint, reflecting stronger CAG Diagnostics recurring revenue performance.”
“Provides initial outlook for 2026 revenue guidance range of $4,632 million - $4,720 million.”
“Increases 2025 revenue guidance to $4,270 million - $4,300 million, an increase of $43 million or ~1% at midpoint.”
Management has consistently raised 2026 EPS guidance, reflecting operational performance, revenue growth, and margin expansion.
Stated as a priority in 4 of last 4 quarters. EPS guidance increased from $14.29-$14.80 at 2025-Q4 to $14.69-$14.94 at 2026-Q2, with reported EPS growth guidance rising from 11%-14% to 12%-14%. Management has consistently raised EPS outlook reflecting operational and revenue growth.
“Increases 2026 EPS outlook to $14.69 - $14.94, reflecting increased reported growth of 12% - 14%.”
Management emphasizes growth in Companion Animal Group Diagnostics recurring revenue driven by innovation, instrument placements, and increased diagnostic utilization.
Stated as a priority in 4 of last 4 quarters. CAG Diagnostics recurring revenue organic growth remained strong at around 10% from 2025-Q3 through 2026-Q2, with reported growth guidance increasing slightly. Management consistently emphasizes innovation, instrument placements, and diagnostic utilization as growth drivers, delivering steady expansion.
“CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic.”
Over the trailing year it converted 1.00x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 43% for the rest of the cohort, n=3313).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
13 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
“Raises 2026 EPS outlook to $14.45 - $14.90, reflecting an increase of $0.13 compared to prior guidance midpoint.”
“Projects 2026 EPS of $14.29 - $14.80.”
“Raises 2025 EPS outlook to $12.81 - $13.01.”
“CAG Diagnostics recurring revenue growth of 14% as reported and 11% organic.”
“CAG Diagnostics recurring revenue growth of 12% as reported and 10% organic.”
“CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic.”